<DOC>
	<DOCNO>NCT01270997</DOCNO>
	<brief_summary>The objective prove equivalence efficacy safety HD203 Enbrel® combination Methotrexate patient rheumatoid arthritis .</brief_summary>
	<brief_title>Randomized Double-blind Parallel Trial Evaluate Equivalence Efficacy Safety HD203 Enbrel RA Patients</brief_title>
	<detailed_description>Primary Objective : To prove equivalence two group compare ACR20 W24 baseline inject HD203 25mg ( Enbrel® ) 25mg patient rheumatoid arthritis 24 week . Secondary Objective : To compare efficacy ACR20 , ACR50 ACR70 , etc along safety adverse event , vital sign , Laboratory test , physical examination immunogenicity , etc two group baseline inject HD203 25mg ( Enbrel® ) 25mg patient rheumatoid arthritis 48 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Males female 20 Patients satisfy classification criterion Rheumatoid Arthritis accord American Colleague Rheumatology ( ACR 1987 ) Patients applicable functional status I III American Colleague Rheumatology Patients autoimmune disease rheumatoid arthritis significant secondary systematic disease cause rheumatoid arthritis Patients currently participate clinical study receive treatment drug sell market experiment Patients significant disease may affect clinical trial judge clinical trial Investigator In opinion investigator , may put patient risk participation study may influence patient ' ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>